Novartis to acquire Avidity Biosciences for about – Business News
Swiss drugmaker Novartis on Sunday mentioned it agreed to acquire US biotech firm Avidity Biosciences for about $12 billion in money, because the company appears to bolster its portfolio of remedies for uncommon muscle issues.
Avidity stockholders will obtain $72 per share in money, representing a premium of 46% to the company’s closing on Friday.
Novartis has been proactively hanging offers this 12 months to deal with the approaching patent cliff for some of its blockbuster medication, together with Entresto for coronary heart failure, Xolair for bronchial asthma and Cosentyx for autoimmune illnesses.
Novartis is increasing into areas with restricted therapy choices with the deal. REUTERS
Under the phrases of the deal, Avidity will separate its early-stage precision cardiology applications into a new company known as Spinco, which is anticipated to be a publicly traded company, Avidity mentioned in a separate assertion.
With this acquisition, Novartis is increasing into areas with restricted therapy choices, whereas strengthening its presence within the uncommon illness panorama.
San-Diego-based Avidity, a clinical-stage company, is developing remedies for numerous muscle issues and advancing a number of first-in-class drug candidates.
Avidity is developing remedies for numerous muscle issues and advancing a number of first-in-class drug candidates. JHVEPhoto – stock.adobe.com
Its lead drug, Del-zota, is in early-to-mid-stage development as a potential therapy for a uncommon type of Duchenne muscular dystrophy, whereas the company can also be engaged on two different medication for critical muscle illnesses.
This deal additionally helps Novartis to determine a stronger foothold within the U.S. market amid a potential hefty pharmaceutical tariff menace from President Trump.
